Kalytera Names Ronald P. Erickson To Board
This article was originally published in Scrip
Kalytera Therapeutics Inc., a company developing a portfolio of non-psychoactive cannanbinoid (CBD) and synthetic CBD medicines, has appointed Ronald P. Erickson to its board of directors. Senior business executive Erickson brings more than 30 years' experience to Kalytera and currently he is the founder, CEO, president and chair of Visualant Inc. He is also on various corporate boards including Bioasis Technologies, a company focused on the delivery of therapeutics across the blood-brain barrier.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.